Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 14,161 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Parkinson Disease, Tremor
Interventions: Placebo, Suvecaltamide; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 21
States / cities: Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 18 more

Conditions: Alzheimer Disease
Interventions: AL002, Placebo; Drug
Lead sponsor: Alector Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 29
States / cities: Phoenix, Arizona • Rogers, Arkansas • Costa Mesa, California + 25 more

Conditions: Normal Pressure Hydrocephalus
Interventions: CereVasc eShunt System, VP Shunt; Device
Lead sponsor: CereVasc Inc; Industry
Eligibility: 60 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 29
States / cities: Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 21 more

Conditions: Abnormal Glucose Tolerance
Interventions: WBF-0031; Dietary Supplement
Lead sponsor: Eden Miller; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Bend, Oregon

Conditions: Food Allergy
Interventions: Viaskin Milk 150 mcg, Viaskin Milk 300 mcg, Viaskin Milk 500 mcg, Viaskin Placebo; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 12
States / cities: Little Rock, Arkansas • San Diego, California • Stanford, California + 9 more

Conditions: Anterior Cervical Discectomy and Fusion (ACDF)
Interventions: Remifentanil, Ketamine, Dexmedetomidine; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 1,829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 75
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more

Conditions: Systemic Lupus Erythematosus
Interventions: CEP-33457, Placebo; Drug
Lead sponsor: Cephalon, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 40
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 33 more

Conditions: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Interventions: Vepugratinib, Placebo, EV, Pembrolizumab; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 64
States / cities: Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 48 more

Conditions: Dementia
Interventions: Tailored Activity Program, Home Safety and Education Program; Behavioral · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19
Interventions: Placebo, Remdesivir, Baricitinib; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 1,033 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 53
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more

Conditions: Sleep Initiation and Maintenance Disorders, Insomnia
Interventions: eplivanserin (SR46349), placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bridgewater, New York

Conditions: Prostate Cancer, Osteoporosis, Fractures
Interventions: Toremifene Citrate; Drug
Lead sponsor: GTx; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 136
States / cities: Homewood, Alabama • Mobile, Alabama • Little Rock, Arkansas + 117 more

Conditions: Epilepsy
Interventions: USL255; Drug
Lead sponsor: Upsher-Smith Laboratories; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 16
States / cities: Phoenix, Arizona • Ventura, California • Gainsville, Florida + 13 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL injection); Drug
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Nampa, Idaho • Hutchinson, Kansas • Kansas City, Kansas + 4 more

Conditions: Sialorrhea
Interventions: MYOBLOC, PLACEBO; Drug · Other
Lead sponsor: Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 24
States / cities: Loma Linda, California • Los Angeles, California • National City, California + 21 more

Conditions: FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin, Amyloidosis
Interventions: Inotersen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 9
States / cities: Orange, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more

Conditions: Hereditary Angioedema (HAE)
Interventions: Recombinant human C1 esterase inhibitor, Placebo, SHP623; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: MN-221, Placebo; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: New Braunfels, Texas • San Antonio, Texas

Conditions: Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Interventions: Placebo Oral Tablet, AGB101 220 mg tablet; Drug
Lead sponsor: AgeneBio; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 23
States / cities: Phoenix, Arizona • Laguna Hills, California • Oceanside, California + 20 more

Conditions: Acute Unilateral Vestibulopathy (AUV)
Interventions: SENS-111 100mg, SENS-111 200mg, Placebo Oral Tablet; Drug
Lead sponsor: Sensorion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: MVA-CMDR, Placebo; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Barth Syndrome
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Psoriatic Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 19
States / cities: Huntsville, Alabama • Palm Desert, California • Palo Alto, California + 16 more

Search by objective public record fields.

A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Effects on Glycemic Control of WBF-0031 in Subjects With Abnormal Glucose Tolerance

Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy

Narcotic Free TIVA and Incidence of Unacceptable Movements Under Anesthesia During ACDF Surgery

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE)

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Reducing Agitation in People With Dementia: the Customized Activity Trial

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia

Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects

Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease

Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis